Intravenous Nicorandil in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary PCI
JACC · 2026
DOI: 10.1016/j.jacc.2026.07.005 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JACC, 2026. Verfasst von Dong Huang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China. Hauptthemen laut MEDLINE: Nicorandil, Percutaneous Coronary Intervention, ST Elevation Myocardial Infarction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: National Major Science and Technology Projects of China, National Natural Science Foundation of China, Shanghai Municipality.
Abstract (Originalsprache)
BACKGROUND: Nicorandil, an adenosine triphosphate-sensitive potassium-channel opener with nitrate-like properties, may reduce reperfusion injury and microvascular obstruction in ST-segment elevation myocardial infarction (STEMI), but large-scale randomized evidence on long-term clinical outcomes is inconclusive. OBJECTIVES: The CLEAN trial aimed to assess whether adjunctive intravenous nicorandil improves 12-month clinical outcomes in patients with STEMI undergoing primary percutaneous coronary intervention. METHODS: In this multicenter, randomized, double-blind, placebo-controlled trial conducted at 49 hospitals in China, patients aged 18 to 80 years with STEMI within 12 hours of symptom onset were randomly assigned (1:1) to receive intravenous nicorandil (6 mg bolus before reperfusion followed by 6 mg/h infusion for 48 h) or matching placebo. Oral nicorandil was prohibited during follow-up. The primary outcome was a composite of cardiovascular death, nonfatal myocardial infarction, target vessel revascularization, or unplanned hospitalization for heart failure within 12 months. RESULTS: Between January 2021 and December 2023, 1,503 patients were enrolled and randomly assigned to nicorandil (n = 748) or placebo (n = 755). The primary composite outcome occurred in 98 patients (13.1%) in the nicorandil group (113 events over 717.2 person-years) and 99 (13.1%) in the placebo group (136 events over 710.3 person-years), with no significant difference between groups (rate ratio: 0.869; 95% CI: 0.650-1.162; P = 0.3429). Among secondary outcomes, nominal reductions were observed in cardiovascular death (1.9% vs 3.6%; HR: 0.515; 95% CI: 0.269-0.983) and target-vessel revascularization (1.1% vs 3.0%; HR: 0.322; 95% CI: 0.143-0.727), whereas rates of nonfatal myocardial infarction and unplanned hospitalization for heart failure were similar between groups. Adverse events did not differ between groups. CONCLUSIONS: In patients with STEMI undergoing primary percutaneous coronary intervention, adjunctive intravenous nicorandil did not significantly reduce the 12-month primary composite outcome. These findings do not support routine use of intravenous nicorandil in unselected patients with STEMI. (Clinical Efficacy and sAfety of Intravenous Nicorandil; NCT04665648).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China.
- Department of Cardiology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
- Department of Cardiology, Kunshan Hospital of Traditional Chinese Medicine, Kunshan, China.
- Department of Cardiology, Taizhou Central Hospital, Taizhou, China.
- Department of Cardiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Cardiology, Anhui Provincial Hospital, Hefei, China.
Förderung
- National Major Science and Technology Projects of China
- National Natural Science Foundation of China
- Shanghai Municipality
Zitieren
APA
Huang, D., Wu, H., Lu, Y., Liu, Q., Cai, H., Shen, J., Ma, L., Yu, Z., Zhao, S., He, S., Peng, W., Zhang, J., Qian, J., Ge, J., & CLEAN Study Group (2026). Intravenous Nicorandil in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary PCI. JACC. https://doi.org/10.1016/j.jacc.2026.07.005
Vancouver
Huang D, Wu H, Lu Y, Liu Q, Cai H, Shen J, et al. Intravenous Nicorandil in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary PCI. JACC. 2026. doi:10.1016/j.jacc.2026.07.005
BibTeX
@article{Huang2026,
author = {Huang, Dong and Wu, Hongxian and Lu, Yuan and Liu, Qingjun and Cai, Haipeng and Shen, Jieyan and Ma, Likun and Yu, Zongliang and Zhao, Shuguang and He, Shenghu and Peng, Wenhui and Zhang, Jinyuan and Qian, Juying and Ge, Junbo and CLEAN Study Group, CLEAN Study Group},
title = {Intravenous Nicorandil in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary PCI},
journal = {JACC},
year = {2026},
doi = {10.1016/j.jacc.2026.07.005}
}
EUVIMED